ReviewJournal of experimental & clinical cancer research : CR2016
Targeting microRNAs as key modulators of tumor immune response.
Review in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.
- Systematic Review of the Prognostic Role of the Immune System After Surgery of Colorectal Liver Metastases.Frontiers in oncology · 2019Pooled it
- Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.BMC cancer · 2023Trial
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- microRNA-1258 suppresses breast cancer progression by targeting LARP4B.Discover oncology · 2025Article
- MicroRNA-mediated regulatory mechanisms in cow's ileum and ileum lymph node in response to Mycobacterium avium subspecies paratuberculosis infection.Scientific reports · 2025Article
- IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer.NAR cancer · 2025Article
- IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells.Cancer biology & therapy · 2025Article
- Young extracellular vesicles restore burn-induced adipose tissue immunometabolic and mitochondrial function in older mice.Scientific reports · 2025Article
- CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Potential of microRNAs as diagnostic markers for distinguishing malaria severity in samples from an Indian cohort.BMC infectious diseases · 2025Article
- Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer.Cancers · 2025Article
- MiR-766-3p Inhibit the Proliferation, Stemness, and Cell Cycle of Pancreatic Cancer Cells Through the MAPK/ERK Signaling Pathway.Molecular genetics & genomic medicine · 2024Article
- miRNAs as Interconnectors between Obesity and Cancer.Non-coding RNA · 2024Review
- MicroRNA-190b Targets RFWD3 in Estrogen Receptor-Positive Breast Cancer.Breast cancer : basic and clinical research · 2024Article
- miR-146a inhibits ovarian tumor growthMolecular therapy oncolytics · 2023Article
- The interaction of mast cells with membranes from lung cancer cells induces the release of extracellular vesicles with a unique miRNA signature.Scientific reports · 2023Article
- MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.Cancer science · 2023Article
- Review
- Intelligent nanotherapeutic strategies for the delivery of CRISPR system.Acta pharmaceutica Sinica. B · 2023Review
- The microRNA target site profile is a novel biomarker in the immunotherapy response.Frontiers in oncology · 2023Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The role of immune response is emerging as a key factor in the complex multistep process of cancer. Tumor microenvironment contains different types of immune cells, which contribute to regulate the fine balance between anti and protumor signals. In this context, mechanisms of crosstalk between cancer and immune cells remain to be extensively elucidated. Interestingly, microRNAs (miRNAs) have been demonstrated to function as crucial regulators of immune response in both physiological and pathological conditions. Specifically, different miRNAs have been reported to have a role in controlling the development and the functions of tumor-associated immune cells. This review aims to describe the most important miRNAs acting as critical modulators of immune response in the context of different solid tumors. In particular, we discuss recent studies that have demonstrated the existence of miRNA-mediated mechanisms regulating the recruitment and the activation status of specific tumor-associated immune cells in the tumor microenvironment. Moreover, various miRNAs have been found to target key cancer-related immune pathways, which concur to mediate the secretion of immunosuppressive or immunostimulating factors by cancer or immune cells. Modalities of miRNA exchange and miRNA-based delivery strategies are also discussed. Based on these findings, the modulation of individual or multiple miRNAs has the potential to enhance or inhibit specific immune subpopulations supporting antitumor immune responses, thus contributing to negatively affect tumorigenesis. New miRNA-based strategies can be developed for more effective immunotherapeutic interventions in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.